Skip to content

Commercial pharmaceutical manufacturing

From first powder to released batch – scaling aseptic production reliably

Learn more

The clinical trials are successful, the approval is in sight – and now the product has to be produced commercially. Will it be a few hundred units per batch or several hundred thousand? The answer shapes every decision that follows.

Commercial manufacturing of sterile drug products covers a wide range: from high-value orphan drugs and advanced therapies filled in small batches to ADCs, biosimilars and vaccines filled on high-speed lines. What all of them share is that most cannot be terminally sterilized – sterility has to be built into every step of the aseptic process.

At the same time, expectations are rising. Annex 1 makes barrier technology and a documented contamination control strategy (CCS) the standard, potent products require operator protection, and supply has to be reliable from day one.

This page brings together what matters for commercial sterile manufacturing – from typical challenges and the right production scale to critical process steps, proven solutions and current trends.

At a glance

Key challenges in commercial manufacturing

  • Choosing the right scale

    Equipment, setup effort and changeovers must match the batch size – otherwise utilization or supply suffers.

  • Sterility assurance under Annex 1

    Barrier technology, minimal interventions and a living CCS are now expected.

  • Potent compounds

    Operators must be protected – from weighing to filling.

  • Decontamination

    Cycles must be effective and fast – without leaving residues that affect the product.

  • Material selection

    Packaging and isolator materials must be carefully chosen and confirmed by testing.

  • Aseptic transfer

    Every item entering Grade A is a potential contamination source.

  • Glove integrity

    Gloves are the most frequent interface between operator and critical zone.

Critical points along the process

Typical commercial process – from powder handling to batch release

  • 1

    Weighing and dispensing

    Active ingredients and excipients are weighed and dispensed. For potent substances, containment protects operators and prevents cross-contamination.

    → Read more about powder handling

  • 2

    Formulation

    Ingredients are dissolved or mixed into the bulk. Solutions that can be sterile-filtered are formulated in closed vessels; products that cannot be filtered must be formulated aseptically in an isolator.

    → Read more about formulation isolators

  • 3

    Component and material supply

    Containers, closures, tools and consumables must enter Grade A continuously – without breaching the barrier or leaving H₂O₂ residuals.

    → Read more about material transfer

  • 4

    Liquid transfer to the filling line

    The bulk solution must reach the filling needles through a closed, sterile path. Sterile filtration, aseptic connections and single-use assemblies reduce cleaning effort and contamination risk.

    → Read more about liquid transfer

  • 5

    Aseptic filling

    The open product is most exposed during filling. Requirements differ strongly with scale: yield and flexibility for small batches, speed and availability for large ones.

    → Read more about small / medium scale filling
    → Read more about large scale filling

  • 6

    Quality control and release

    Environmental monitoring shows whether the process stayed under control; the sterility test is the final step before release.

    → Read more about sterility testing

Key topics across the process

Regulatory framework and operator protection

Some topics matter at every step and every scale. Each is introduced briefly here and explored in depth on its own page or in the related whitepapers.

  • Annex 1 and contamination control strategy

    Annex 1 makes a documented, living CCS the basis of every design decision – from barrier technology to monitoring.

    → Overview: Annex 1 and its impact on isolator design

  • Containment

    Containment performance must match the substance, the quantity and the process step – and be verified, not assumed.

    → Whitepaper: “The Containment Matrix of the ISPE D/A/CH CoP Containment”

Open isolator interior of Robocell filling line with integrated glove ports and material handling area.
Key topics across the process

Decontamination and materials

Key topics across the process

Physical interfaces

  • Aseptic transfer

    Every item that enters Grade A – packaging materials, tools, format parts, consumables and liquids – is a potential contamination source, which is why Annex 1 pays particular attention to transfers. The right system depends on the material, the throughput and the barrier system.

    → Overview: Comparison of aseptic transfer systems and their applications

  • Glove management

    Gloves are the most frequent contact point between operator and critical zone – and one of the most vulnerable parts of the barrier. A robust glove management concept covers the choice of glove material, regular integrity testing, and defined exchange intervals and procedures.

A gloved hand inserting a white aseptic transfer nozzle into a stainless steel port with locking latches.

Expertise for commercial manufacturing

Commercial aseptic manufacturing needs more than individual machines – barrier, transfer, decontamination, containment and data have to work together. With over five decades of experience and more than 1,500 isolators installed, SKAN covers the full range, from process isolators for weighing to high-speed filling lines.

Every solution starts with the customer’s process, not a fixed platform. SKAN tailors each isolator to the product, site and goals – integrating filling and lyophilization equipment from other suppliers, fitting into existing buildings and accommodating special formats or process steps. Requirements are refined together and tested on mock-ups before fabrication.

This approach is not limited to filling lines. Wherever a pharmaceutical process needs protection – from weighing and formulation to moving materials between rooms or bringing aseptic conditions to where they are needed – SKAN designs the isolator around it and integrates the required process equipment. Many of these special applications started with a single customer request.

Applied science, material testing and active work in ISPE, PDA and ISO groups help translate Annex 1 into inspection-ready designs. Retrofits, requalification and worldwide service keep lines compliant for decades.

Let’s talk about your commercial manufacturing

Planning a new line or scaling an existing process? Let’s discuss your product, batch sizes and timeline.

Back to top